jmt101
mAbexperimental
Clinical trial activity
12 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
4
Phase 4
0
Earliest trial started Apr 11, 2017 (NCT04689100)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07134205 | Phase 3 | Oct 1, 2025 | Shanghai JMT-Bio Inc. |
| NCT06989671 | Phase 2 | Aug 30, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT06892431 | Phase 2 | Apr 1, 2025 | Shanghai JMT-Bio Inc. |
| NCT06735391 | Phase 3 | Oct 23, 2024 | Shanghai JMT-Bio Inc. |
| NCT06319313 | Phase 2/Phase 3 (Phase 3) | May 1, 2024 | Shanghai JMT-Bio Inc., Sun Yat-Sen University |
| NCT06380348 | Phase 3 | Apr 26, 2024 | Shanghai JMT-Bio Inc. |
| NCT06089330 | Phase 2 | Jan 31, 2024 | Shanghai JMT-Bio Inc. |
| NCT05164848 | Phase 1 | Dec 25, 2021 | Chinese Academy of Medical Sciences, Peking University |
| NCT06391944 | Phase 2 | Nov 21, 2021 | Shanghai JMT-Bio Inc., Sun Yat-Sen University |
| NCT05132777 | Phase 2 | Nov 20, 2021 | Shanghai JMT-Bio Inc., Shijiazhuang Pharma Group (CSPC), Sun Yat-Sen University |
| NCT04448379 | Phase 1 | Jun 29, 2020 | Shanghai JMT-Bio Inc., Shijiazhuang Pharma Group (CSPC) |
| NCT04689100 | Phase 1 | Apr 11, 2017 | Shanghai JMT-Bio Inc., Shijiazhuang Pharma Group (CSPC) |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai JMT-Bio Inc. | For profit | 10 | 10 | 3 | 2017 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 4 | 1 | 2 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 0 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1